CO2022015737A2 - Anticuerpos anti-phf-tau y usos de los mismos - Google Patents

Anticuerpos anti-phf-tau y usos de los mismos

Info

Publication number
CO2022015737A2
CO2022015737A2 CONC2022/0015737A CO2022015737A CO2022015737A2 CO 2022015737 A2 CO2022015737 A2 CO 2022015737A2 CO 2022015737 A CO2022015737 A CO 2022015737A CO 2022015737 A2 CO2022015737 A2 CO 2022015737A2
Authority
CO
Colombia
Prior art keywords
container
pull tab
phf
package
tau antibodies
Prior art date
Application number
CONC2022/0015737A
Other languages
English (en)
Inventor
Jinquan Luo
Marc Mercken
Sanjaya Singh
Porte Sherry La
Sathyadevi Venkataramani
Kolen Kristof Van
Rupesh Nanjunda
Pharavee Jaiprasart
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CO2022015737A2 publication Critical patent/CO2022015737A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)

Abstract

Un envase (10) que incluye un contenedor (12) y un cierre de contenedor (14) que tiene una pestaña para jalar indicando vacío (30, 130, 230); el contenedor incluye un eje longitudinal (A) extendiéndose a través del mismo, una boca (24), y una superficie de sellado (26); el cierre de contenedor incluye una membrana de sello (28) acoplada de manera sellada y desmontable a la superficie de sellado del contenedor para sellar el contenedor, y la pestaña para jalar está configurada para extenderse desde la membrana de sello; la manipulación de la pestaña para jalar proporciona una indicación de la presencia o ausencia de un vacío en el envase.
CONC2022/0015737A 2020-04-08 2022-10-31 Anticuerpos anti-phf-tau y usos de los mismos CO2022015737A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18
PCT/IB2021/052890 WO2021205359A1 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2022015737A2 true CO2022015737A2 (es) 2023-02-27

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015737A CO2022015737A2 (es) 2020-04-08 2022-10-31 Anticuerpos anti-phf-tau y usos de los mismos

Country Status (18)

Country Link
US (1) US20230151083A1 (es)
EP (1) EP4132569A4 (es)
JP (1) JP2023521763A (es)
KR (1) KR20220166308A (es)
CN (1) CN115697393A (es)
AU (1) AU2021251486A1 (es)
BR (1) BR112022020410A2 (es)
CA (1) CA3179914A1 (es)
CL (1) CL2022002766A1 (es)
CO (1) CO2022015737A2 (es)
CR (1) CR20220505A (es)
DO (1) DOP2022000218A (es)
EC (1) ECSP22078815A (es)
IL (1) IL297231A (es)
MX (1) MX2022012628A (es)
PE (1) PE20230385A1 (es)
TW (1) TW202204402A (es)
WO (1) WO2021205359A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202346355A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
WO2023170295A1 (en) * 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578567A1 (en) * 2011-12-20 2019-12-11 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
PE20180499A1 (es) * 2015-07-06 2018-03-09 Ucb Biopharma Sprl Anticuerpos de union a tau
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها

Also Published As

Publication number Publication date
WO2021205359A1 (en) 2021-10-14
TW202204402A (zh) 2022-02-01
EP4132569A1 (en) 2023-02-15
ECSP22078815A (es) 2022-11-30
JP2023521763A (ja) 2023-05-25
EP4132569A4 (en) 2024-07-31
BR112022020410A2 (pt) 2023-01-03
MX2022012628A (es) 2023-01-11
IL297231A (en) 2022-12-01
CL2022002766A1 (es) 2023-04-21
CR20220505A (es) 2023-05-31
AU2021251486A1 (en) 2022-12-08
PE20230385A1 (es) 2023-03-06
US20230151083A1 (en) 2023-05-18
CA3179914A1 (en) 2021-10-14
CN115697393A (zh) 2023-02-03
KR20220166308A (ko) 2022-12-16
DOP2022000218A (es) 2023-04-30

Similar Documents

Publication Publication Date Title
CO2022015737A2 (es) Anticuerpos anti-phf-tau y usos de los mismos
AR085601A1 (es) Cierre con caracteristica a prueba de manipulacion
US2394722A (en) Nursing bottle
AR046175A1 (es) Una valvula unidireccional liberadora de presion aplicable a un envase que contiene un producto que emite gases, en la que coexisten un medio fluido y una burbuja de aire, y un envase que incluye a dicha valvula
RU2010140905A (ru) Обратный клапан
BRPI0805849A2 (pt) dispositivo para dispensar, por meio de uma bomba, substáncias fluidas contidas em condições de impermeabilidade ao ar em uma bolsa deformável abrigada em um recipiente rìgido
AR043240A1 (es) Envoltura termo-contraible
US3476507A (en) Medical sterilization apparatus
CO2020008831A2 (es) Cierre de contenedor con pestaña para jalar indicando vacío
WO2015008085A3 (en) Closure device, apparatus and method
ES2154255T1 (es) Biberones para bebes.
AR117851A1 (es) Difusor para recipiente a presión
CL2021001030A1 (es) Cierre para un caño de un envase flexible de paredes delgadas
CL2018000518A1 (es) Sistema de receptáculo y cierre
AR095584A1 (es) Mecha para indicar apertura de envase
JP6143769B2 (ja) 中空で取外し可能な蓋を含む容器
MX2018009017A (es) Unidad de tapa de cierre.
US996330A (en) Liquid-dropper.
AR119458A1 (es) Copela de válvula para recipiente a presión
CL2017002288A1 (es) Revestimientos metalizados sellantes para envases
CN207985731U (zh) 一种抽气密封盖
US1366789A (en) Liquid-receptacle attachment
CN203096144U (zh) 水银回吸器
PE20220895A1 (es) Canto circular de tapa para recipientes de vidrio
AR108182A1 (es) Dispositivo adaptable a válvulas para el llenado manual de envases con líquidos liberadores de co₂